Nyt fra tidsskrifterne
Søgeord (tixagevimab) valgt.
22 emner vises.
1
Risk of SARS-CoV-2 infection in patients with hematologic diseases receiving tixagevimab/cilgavimab as pre-exposure prophylaxis in most recent Omicron sublineages era
International Journal of Infectious Diseases
Tilføjet 12.04.2024
2
Correspondence: serum neutralization of SARS-CoV-2 Omicron sublineages BA.1, BA.2 and BA.5 in lung transplant recipients receiving prophylactic tixagevimab/cilgavimab
Infection
Tilføjet 10.04.2024
3
Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19
Antimicrobial Agents And Chemotherapy
Tilføjet 27.03.2024
4
Clinical and Virological Outcome of Monoclonal Antibody Therapies Across Severe Acute Respiratory Syndrome Coronavirus 2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study
Clinical Infectious Diseases
Tilføjet 6.03.2024
5
Spike protein genetic evolution in patients at high-risk of severe COVID-19 treated by monoclonal antibodies
Journal of Infectious Diseases
Tilføjet 25.11.2023
6
Role of tixagevimab‐cilgavimab in preventing SARS‐CoV‐2 in hematopoietic stem cell transplant and chimeric antigen receptor T‐cell therapy recipients
Journal of Medical Virology
Tilføjet 8.08.2023
7
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated with AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants
Journal of Infectious Diseases
Tilføjet 7.06.2023
8
Efficacy and safety of tixagevimab‐cilgavimab as pre‐exposure prophylaxis for COVID‐19: A systematic review and meta‐analysis
Reviews in Medical Virology
Tilføjet 24.04.2023
9
Efficacy of pre-exposure prophylaxis to prevent SARS-CoV-2 infection after lung transplantation: a two center cohort study during the omicron era
Infection
Tilføjet 17.03.2023
10
Updated COVID-19 Guidance for People Who Are Immunocompromised
Journal of the American Medical Association
Tilføjet 1.03.2023
11
Tixagevimab/Cilgavimab Treatment and Cardiovascular Events: Immortal time bias
Clinical Infectious Diseases
Tilføjet 18.02.2023
12
Safety, Tolerability and Pharmacokinetics of Half-Life Extended SARS-CoV-2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab/Cilgavimab) in Healthy Adults
Journal of Infectious Diseases
Tilføjet 23.01.2023
13
Increased Reporting of Venous and Arterial Thromboembolic events reported with Tixagevimab–Cilgavimab for COVID-19
Clinical Microbiology and Infection
Tilføjet 2.12.2022
14
AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of Symptomatic COVID-19
Clinical Infectious Diseases
Tilføjet 22.11.2022
15
Cardiovascular outcomes after tixagevimab and cilgavimab use for pre-exposure prophylaxis against COVID-19: a population-based propensity-matched cohort study
Clinical Infectious Diseases
Tilføjet 17.11.2022
16
Monoclonals for patients hospitalised with COVID-19
Lancet Respiratory Medicine
Tilføjet 28.09.2022
17
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial
Lancet Respiratory Medicine
Tilføjet 28.09.2022
18
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
Lancet Respiratory Medicine
Tilføjet 28.09.2022
19
Patient Information: Preventive Medication for COVID-19 Infection
Journal of the American Medical Association
Tilføjet 20.09.2022
20
Evusheld Treatment Timing Set
Journal of the American Medical Association
Tilføjet 16.08.2022
21
Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld©) for COVID-19 among 1112 severely immunocompromised patients
Clinical Microbiology and Infection
Tilføjet 1.08.2022
22
Evusheld Reduces COVID-19 Disease Severity Among Unvaccinated Adults
Journal of the American Medical Association
Tilføjet 26.07.2022